Case report: Long-lasting SARS-CoV-2 infection with post-COVID-19 condition in two patients with chronic lymphocytic leukemia: The emerging therapeutic role of casirivimab/imdevimab

Case report: Long-lasting SARS-CoV-2 infection with post-COVID-19 condition in two patients with chronic lymphocytic leukemia: The emerging therapeutic role of casirivimab/imdevimab

Post-coronavirus disease 2019 (post-COVID-19) condition, previously referred to as long COVID, includes a post-acute syndrome defined by the presence of non-specific symptoms occurring usually 3 months from the onset of the acute phase and lasting at least 2 months. Patients with chronic lymphocytic...

Full description

Bibliographic Details
Main Authors: Laura Ballotta, Omar Simonetti, Pierlanfranco D’Agaro, Ludovica Segat, Raffaella Koncan, Pamela Martinez-Orellana, Federica Dattola, Emanuele Orsini, Alessandro Marcello, Simeone Dal Monego, Danilo Licastro, Andrea Misin, Sara Mohamed, Eugenio Sbisà, Elisa Lucchini, Giovanni Maria De Sabbata, Francesco Zaja, Roberto Luzzati
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Oncology
Subjects:
chronic lymphocyte leukemia
COVID - 19
monoclonal antibodies
casirivimab/imdevimab
post COVID-19 condition
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.945060/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.945060/full

Similar Items